Company profile
Vir Biotechnology, Inc.
Pipeline6 assets
- ElebsiranVIR-2218 / HBV / siRNA / Infectious DiseasesChronic Hepatitis Delta (CHD)Phase 3ActiveGlobalChronic Hepatitis B (CHB)Phase 2ActiveGlobal
- TobevibartVIR-3434 / HBV / Monoclonal Antibody / Infectious DiseasesChronic Hepatitis Delta (CHD)Phase 3ActiveGlobalChronic Hepatitis B (CHB)Phase 2ActiveGlobal
- VIR-1388VIR-1388 / HIV / T Cell Vaccine / Infectious DiseasesHIV PreventionPhase 1ActiveUnited StatesSouth Africa
- VIR-5500VIR-5500 / PSMA / Masked T-Cell Engager / OncologySolid TumorsPhase 1ActiveGlobal
- VIR-5525VIR-5525 / EGFR / Masked T-Cell Engager / OncologySolid TumorsPhase 1ActiveGlobal
- VIR-5818VIR-5818 / HER2 / Masked T-Cell Engager / OncologySolid TumorsPhase 1ActiveGlobal